Get the Weekly Intelligence Brief — top committee picks every Sunday.

CHE vs PTGX

Chemed Corp. vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
CHE
Chemed Corp.
64
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
64
Buy
MetricCHEPTGX
AI Score 64 64
Price $541.60 $151.99
P/E Ratio 26.96× 121.74×
ROE 27.1% -21.2%
Revenue Growth YoY
Gross Margin 30.4% 99.9%
Debt / Equity 0.35× 0.01×
Dividend Yield 0.4% 0.0%
RSI (14) 53.7 68.1
Beta 0.511 1.794
Expected Upside +0.2%

AI Committee View

Current Innellis committee reasoning for CHE versus PTGX.
The committee scores are tied.

CHE and PTGX both score 64/100.

CHE Committee View
67% agreement
6 analysts

The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 26.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 29.4% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
Bear Case
  • P/E of 26.2 is moderate-to-rich — Value
  • Price-to-book of 6.2x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
PTGX Committee View
67% agreement
6 analysts

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
  • EPS growing 46.0% YoY — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • P/E of 115.4 is expensive by classic value standards — Value
  • Price-to-book of 8.9x prices in significant intangible value — Value
  • Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
CHE Full Analysis PTGX Full Analysis